Login to Your Account



Resverlogix's Phase IIb Results Good for 'Bromodomain' Drugs

By Catherine Shaffer
Staff Writer

Wednesday, August 29, 2012
Resverlogix Corp. reported success in a Phase IIb (SUSTAIN) trial of its small-molecule BET protein inhibitor, RVX-208, designed to increase levels of high-density lipoprotein cholesterol (HDL-C) in patients with atherosclerosis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription